{"id":"NCT03393754","sponsor":"VBI Vaccines Inc.","briefTitle":"Immunogenicity and Safety of Sci-B-Vac® to Engerix-B® in Adults","officialTitle":"A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac® to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-12-13","primaryCompletion":"2019-04-08","completion":"2019-04-08","firstPosted":"2018-01-08","resultsPosted":"2020-07-07","lastUpdate":"2020-07-17"},"enrollment":1607,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Hepatitis B Vaccines"],"interventions":[{"type":"BIOLOGICAL","name":"Hepatitis B Vaccination","otherNames":[]}],"arms":[{"label":"Sci-B-Vac® Hepatitis B Vaccination","type":"EXPERIMENTAL"},{"label":"Engerix-B® Hepatitis B Vaccination","type":"ACTIVE_COMPARATOR"}],"summary":"This study is a double-blind randomized controlled trial designed to establish the non-inferiority of Sci-B-Vac® compared to Engerix-B® in adults ≥ 18 years old and the superiority of Sci-B-Vac® compared to Engerix-B® in ≥ 45 years old.","primaryOutcome":{"measure":"Seroprotection Rate (SPR) Defined as Percentage of Adults ≥ 18 Years Old Achieving Anti-HBs Levels of ≥10 mIU/mL in Serum at Study Day 196","timeFrame":"Day 196","effectByArm":[{"arm":"Engerix-B® Hepatitis B Vaccination","deltaMin":76.49,"sd":null},{"arm":"Sci-B-Vac® Hepatitis B Vaccination","deltaMin":91.36,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":28,"countries":["United States","Belgium","Canada","Finland"]},"refs":{"pmids":["39536477","37147201","33989539"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":811},"commonTop":["Headache","Upper respiratory tract infection","Fatigue","Nasopharyngitis","Myalgia"]}}